Logotype for Clearside Biomedical Inc

Clearside Biomedical (CLSDQ) Q4 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Clearside Biomedical Inc

Q4 2024 earnings summary

24 Dec, 2025

Executive summary

  • Achieved FDA alignment on pivotal phase III program for CLS-AX in wet AMD following positive phase II-B results, confirming protocol design and endpoints.

  • Suprachoroidal delivery platform validated by partners, with approvals in Australia and Singapore and regulatory review in China for Arcatus (XIPERE).

  • Multiple global phase III trials planned or ongoing with partners in diabetic retinopathy, choroidal melanoma, DME, gene therapy, and ocular oncology.

  • Internal pipeline expansion includes small molecule candidates for geographic atrophy and other ophthalmic indications.

  • Appointed Tony Gibney as Chair of the Board, bringing significant biotech and business development experience.

Financial highlights

  • Cash and cash equivalents totaled $20.0 million as of December 31, 2024, sufficient to fund operations into Q4 2025.

  • Q4 2024 license and other revenue was $0.3M, down from $6.3M in Q4 2023, due to prior year milestone payments.

  • Q4 2024 net loss was $7.3M ($0.10/share) vs. $4.8M ($0.08/share) in Q4 2023; full year 2024 net loss was $34.4M ($0.47/share) vs. $32.5M ($0.53/share) in 2023.

  • R&D expenses for Q4 2024 were $4.2M, down from $6.3M in Q4 2023; full year R&D was $18.6M, down from $20.8M.

Outlook and guidance

  • Actively pursuing funding options for the CLS-AX phase III program, including potential partnerships.

  • Targeting initiation of phase III trial in the second half of the year, contingent on securing funding.

  • Pipeline expansion opportunities identified in geographic atrophy, diabetic retinopathy, and diabetic macular edema.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more